Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GMTXNASDAQ:LNTHNASDAQ:ROIVNASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMTXGemini Therapeutics$43.55+2.3%$47.36$1.16▼$14.10$1.89B-0.12189,291 shs601,399 shsLNTHLantheus$80.16-0.4%$99.90$74.34▼$126.89$5.49B0.23963,970 shs2.98 million shsROIVRoivant Sciences$11.03-1.3%$10.46$8.73▼$13.06$7.87B1.235.54 million shs5.80 million shsRVMDRevolution Medicines$42.01+11.6%$37.23$29.17▼$62.40$7.83B1.111.49 million shs6.59 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMTXGemini Therapeutics-12.40%-9.70%+3.29%-23.99%+41.73%LNTHLantheus-23.19%-22.82%-15.63%-11.41%+5.94%ROIVRoivant Sciences+0.99%-3.87%+20.63%+2.76%-1.85%RVMDRevolution Medicines+0.59%-6.74%+19.94%-13.56%-3.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGMTXGemini TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ALNTHLantheus4.2267 of 5 stars3.51.00.04.22.02.51.9ROIVRoivant Sciences2.2976 of 5 stars3.51.00.00.04.22.50.0RVMDRevolution Medicines4.3201 of 5 stars4.50.00.04.73.92.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMTXGemini Therapeutics 0.00N/AN/AN/ALNTHLantheus 3.00Buy$132.6765.50% UpsideROIVRoivant Sciences 3.00Buy$17.5058.66% UpsideRVMDRevolution Medicines 3.00Buy$67.1759.87% UpsideCurrent Analyst Ratings BreakdownLatest GMTX, ROIV, RVMD, and LNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025LNTHLantheusTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$127.00 ➝ $117.005/8/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$67.005/8/2025RVMDRevolution MedicinesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$70.00 ➝ $75.005/8/2025RVMDRevolution MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$87.00 ➝ $80.005/8/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$57.00 ➝ $57.004/28/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$67.00 ➝ $67.004/21/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.004/8/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$59.00 ➝ $59.004/1/2025RVMDRevolution MedicinesStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$78.00 ➝ $64.003/21/2025LNTHLantheusB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$127.00 ➝ $122.003/4/2025ROIVRoivant SciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/ALNTHLantheus$1.53B3.58$6.69 per share11.98$11.91 per share6.73ROIVRoivant Sciences$122.59M64.20N/AN/A$7.76 per share1.42RVMDRevolution Medicines$742K10,546.40N/AN/A$11.09 per share3.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/ALNTHLantheus$326.66M$4.3713.3412.70N/A28.57%44.29%23.52%N/AROIVRoivant Sciences$4.35B-$0.15N/AN/AN/A-119.54%-14.05%-12.81%5/29/2025 (Estimated)RVMDRevolution Medicines-$436.37M-$3.57N/AN/AN/AN/A-33.67%-30.08%N/ALatest GMTX, ROIV, RVMD, and LNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2025Q4 2025ROIVRoivant Sciences-$0.16N/AN/AN/A$62.17 millionN/A5/7/2025Q1 2025LNTHLantheus$1.64$1.53-$0.11$1.02$377.37 million$372.76 million5/7/2025Q1 2025RVMDRevolution Medicines-$1.12-$1.13-$0.01-$1.13N/AN/A2/27/2025Q4 2024LNTHLantheus$1.57$1.34-$0.23-$0.17$376.61 million$391.11 million2/26/2025Q4 2024RVMDRevolution Medicines-$1.01-$1.12-$0.11-$1.12$0.35 millionN/A2/10/2025Q3 2025ROIVRoivant Sciences-$0.24-$0.20+$0.04$0.23$4.75 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGMTXGemini TherapeuticsN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMTXGemini TherapeuticsN/A71.4971.49LNTHLantheusN/A1.651.56ROIVRoivant SciencesN/A37.9137.91RVMDRevolution MedicinesN/A14.2414.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMTXGemini Therapeutics75.42%LNTHLantheus99.06%ROIVRoivant Sciences64.76%RVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipGMTXGemini Therapeutics12.90%LNTHLantheus2.00%ROIVRoivant Sciences7.90%RVMDRevolution Medicines8.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableLNTHLantheus70068.48 million68.48 millionOptionableROIVRoivant Sciences860713.55 million657.18 millionOptionableRVMDRevolution Medicines250186.26 million154.76 millionOptionableGMTX, ROIV, RVMD, and LNTH HeadlinesRecent News About These CompaniesRevolution Medicines, Inc. (NASDAQ:RVMD) Holdings Cut by Casdin Capital LLCMay 8 at 7:13 AM | marketbeat.comRevolution Medicines, Inc. (RVMD) Q1 2025 Earnings Call TranscriptMay 7 at 7:03 PM | seekingalpha.comRevolution Medicines, Inc. 2025 Q1 - Results - Earnings Call PresentationMay 7 at 6:59 PM | seekingalpha.comRevolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate ProgressMay 7 at 4:02 PM | globenewswire.comBalyasny Asset Management L.P. Sells 348,957 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)May 7 at 6:15 AM | marketbeat.comThe Manufacturers Life Insurance Company Buys 24,698 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)May 7 at 4:36 AM | marketbeat.comAvidity Partners Management LP Reduces Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD)May 6 at 7:39 AM | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Holdings Boosted by Baker BROS. Advisors LPMay 6 at 7:39 AM | marketbeat.comBVF Inc. IL Acquires 702,567 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)May 6 at 7:30 AM | marketbeat.comBellevue Group AG Cuts Position in Revolution Medicines, Inc. (NASDAQ:RVMD)May 6 at 6:32 AM | marketbeat.comBoxer Capital Management LLC Buys Shares of 4,279,464 Revolution Medicines, Inc. (NASDAQ:RVMD)May 4, 2025 | marketbeat.comRevolution Medicines (RVMD) Projected to Post Quarterly Earnings on WednesdayMay 4, 2025 | marketbeat.comFirst Trust Advisors LP Sells 35,269 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)May 3, 2025 | marketbeat.comRevolution Medicines (RVMD) Expected to Announce Quarterly Earnings on WednesdayMay 2, 2025 | americanbankingnews.comRevolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025April 30, 2025 | globenewswire.comRevolution Medicines (NASDAQ:RVMD) Shares Up 5.8% - Should You Buy?April 30, 2025 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Given "Outperform" Rating at WedbushApril 30, 2025 | marketbeat.comHsbc Holdings PLC Trims Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)April 30, 2025 | marketbeat.comWedbush Reiterates Outperform Rating for Revolution Medicines (NASDAQ:RVMD)April 30, 2025 | americanbankingnews.comArtia Global Partners LP Raises Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)April 29, 2025 | marketbeat.comWhy Revolution Medicines, Inc.’s (RVMD) Stock Is Up 5.47%April 29, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGMTX, ROIV, RVMD, and LNTH Company DescriptionsGemini Therapeutics NASDAQ:GMTX$43.55 +0.98 (+2.29%) As of 05/7/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.Lantheus NASDAQ:LNTH$80.16 -0.33 (-0.41%) Closing price 03:59 PM EasternExtended Trading$80.45 +0.29 (+0.36%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Roivant Sciences NASDAQ:ROIV$11.03 -0.14 (-1.25%) Closing price 04:00 PM EasternExtended Trading$11.03 0.00 (0.00%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Revolution Medicines NASDAQ:RVMD$42.01 +4.35 (+11.56%) Closing price 03:59 PM EasternExtended Trading$41.91 -0.10 (-0.25%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Energy Transfer Undervalued or a Value Trap? Carvana’s Stock Price Rebound Shifts Into a Higher Gear Why Investors Should Be Careful About AMC's Bitcoin Dreams Alphabet Slumps as Apple Eyes AI Search—Is the Sell-Off Overdone? Joby's Q1: Key Milestones Achieved as Path to Market Crystalizes Rockwell Automation: Tailwinds From Onshoring U.S. Production IBM's AI Offensive: Assessing IBM's Path to Renewed Growth Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
